Replies to post #172134 on Biotech Values

[DewDiligence]

RVNC IPO’s 6.9M* shares @16.00:

http://finance.yahoo.com/news/revance-therapeutics-announces-pricing-initial-021500974.html

Revance Therapeutics, Inc. is a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS, that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.

I’m pretty skeptical of this technology, as noted in #msg-95531872.

*Assuming exercise of underwriter’s option.